350 related articles for article (PubMed ID: 21207640)
1. [Assessment of fecal calprotectin concentration as inflammatory marker in inflammatory bowel diseases in children--preliminary report].
Krzesiek E; Iwańczak B
Pol Merkur Lekarski; 2010 Oct; 29(172):241-6. PubMed ID: 21207640
[TBL] [Abstract][Full Text] [Related]
2. Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease.
Canani RB; Terrin G; Rapacciuolo L; Miele E; Siani MC; Puzone C; Cosenza L; Staiano A; Troncone R
Dig Liver Dis; 2008 Jul; 40(7):547-53. PubMed ID: 18358796
[TBL] [Abstract][Full Text] [Related]
3. Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease.
Gisbert JP; McNicholl AG
Dig Liver Dis; 2009 Jan; 41(1):56-66. PubMed ID: 18602356
[TBL] [Abstract][Full Text] [Related]
4. Fecal calprotectin remains high during glucocorticoid therapy in children with inflammatory bowel disease.
Kolho KL; Raivio T; Lindahl H; Savilahti E
Scand J Gastroenterol; 2006 Jun; 41(6):720-5. PubMed ID: 16716972
[TBL] [Abstract][Full Text] [Related]
5. [Measurement of calprotectin in faeces].
Jahnsen J; Røseth AG; Aadland E
Tidsskr Nor Laegeforen; 2009 Apr; 129(8):743-5. PubMed ID: 19373299
[TBL] [Abstract][Full Text] [Related]
6. Fecal calprotectin: a quantitative marker of colonic inflammation in children with inflammatory bowel disease.
Fagerberg UL; Lööf L; Lindholm J; Hansson LO; Finkel Y
J Pediatr Gastroenterol Nutr; 2007 Oct; 45(4):414-20. PubMed ID: 18030206
[TBL] [Abstract][Full Text] [Related]
7. Rectal nitric oxide and fecal calprotectin in inflammatory bowel disease.
Reinders CA; Jonkers D; Janson EA; Stockbrügger RW; Stobberingh EE; Hellström PM; Lundberg JO
Scand J Gastroenterol; 2007 Oct; 42(10):1151-7. PubMed ID: 17852876
[TBL] [Abstract][Full Text] [Related]
8. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.
Langhorst J; Elsenbruch S; Koelzer J; Rueffer A; Michalsen A; Dobos GJ
Am J Gastroenterol; 2008 Jan; 103(1):162-9. PubMed ID: 17916108
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic value of calprotectin in irritable bowel syndrome and in inflammatory bowel disease.
Grad C; David L; Portincasa P; Dumitraşcu DL
Rom J Intern Med; 2012; 50(1):3-6. PubMed ID: 22788087
[TBL] [Abstract][Full Text] [Related]
10. Review of fecal biomarkers in inflammatory bowel disease.
Sutherland AD; Gearry RB; Frizelle FA
Dis Colon Rectum; 2008 Aug; 51(8):1283-91. PubMed ID: 18543035
[TBL] [Abstract][Full Text] [Related]
11. Clinical utility of calprotectin and lactoferrin as markers of inflammation in patients with inflammatory bowel disease.
Caccaro R; D'Incá R; Sturniolo GC
Expert Rev Clin Immunol; 2010 Jul; 6(4):551-8. PubMed ID: 20594128
[TBL] [Abstract][Full Text] [Related]
12. [Calprotectin: a fecal marker for diagnosis and follow-up in patients with chronic inflammatory bowel disease].
van den Bergh FA; Kolkman JJ; Russel MG; Vlaskamp RT; Vermes I
Ned Tijdschr Geneeskd; 2003 Nov; 147(48):2360-5. PubMed ID: 14677476
[TBL] [Abstract][Full Text] [Related]
13. Prospective evaluation of faecal neutrophil-derived proteins in identifying intestinal inflammation: combination of parameters does not improve diagnostic accuracy of calprotectin.
Schröder O; Naumann M; Shastri Y; Povse N; Stein J
Aliment Pharmacol Ther; 2007 Oct; 26(7):1035-42. PubMed ID: 17877510
[TBL] [Abstract][Full Text] [Related]
14. Fecal calprotectin and lactoferrin as noninvasive markers of pediatric inflammatory bowel disease.
Joishy M; Davies I; Ahmed M; Wassel J; Davies K; Sayers A; Jenkins H
J Pediatr Gastroenterol Nutr; 2009 Jan; 48(1):48-54. PubMed ID: 19172123
[TBL] [Abstract][Full Text] [Related]
15. Comparison of a novel fecal marker--fecal tumor pyruvate kinase type M2 (M2-PK) with fecal calprotectin in patients with inflammatory bowel disease: a prospective study.
Shastri YM; Povse N; Schröder O; Stein J
Clin Lab; 2008; 54(9-10):389-90. PubMed ID: 19097497
[No Abstract] [Full Text] [Related]
16. Utility of fecal calprotectin in differentiating active inflammatory bowel disease from coexistent irritable bowel syndrome.
Sprakes MB; Hamlin PJ; Ford AC
Am J Gastroenterol; 2011 Jan; 106(1):166; author reply 166-7. PubMed ID: 21212757
[No Abstract] [Full Text] [Related]
17. Faecal calprotectin: a new marker for Crohn's disease?
Wassell J; Dolwani S; Metzner M; Losty H; Hawthorne A
Ann Clin Biochem; 2004 May; 41(Pt 3):230-2. PubMed ID: 15117438
[TBL] [Abstract][Full Text] [Related]
18. Technology insight: calprotectin, lactoferrin and nitric oxide as novel markers of inflammatory bowel disease.
Lundberg JO; Hellström PM; Fagerhol MK; Weitzberg E; Roseth AG
Nat Clin Pract Gastroenterol Hepatol; 2005 Feb; 2(2):96-102. PubMed ID: 16265127
[TBL] [Abstract][Full Text] [Related]
19. [Faecal calprotectin in inflammatory bowel diseases: review].
Kallel L; Fekih M; Boubaker J; Filali A
Tunis Med; 2011 May; 89(5):425-9. PubMed ID: 21557177
[TBL] [Abstract][Full Text] [Related]
20. Fecal calprotectin as a promising marker of inflammatory diseases.
Paduchova Z; Durackova Z
Bratisl Lek Listy; 2009; 110(10):598-602. PubMed ID: 20017448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
